-
1.发明申请公开(公告)号：US20090004177A1
公开(公告)日：2009-01-01
申请号：US12185588
申请日：2008-08-04
申请人： Paul Armstrong , Hal Barron , Silvano Berioli , Frederique Bigonzi , Erich Bluhmki , Richard Chin , Christopher Granger , Frans Van De Werf , Fong Wang-Clow
发明人： Paul Armstrong , Hal Barron , Silvano Berioli , Frederique Bigonzi , Erich Bluhmki , Richard Chin , Christopher Granger , Frans Van De Werf , Fong Wang-Clow
CPC分类号： A61K38/49 , G06Q99/00 , A61K2300/00
摘要： The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
摘要翻译： 本发明涉及用于治疗血栓溶解病症（例如急性心肌梗死（AMI））的改进的治疗方案。 特别地，本发明涉及血栓溶解障碍（例如AMI）的治疗，与野生型人t-型细胞相比，组合纤溶酶原激活剂（t-PA）变体具有改善的纤维蛋白特异性和延长的血浆半衰期， PA和低分子量肝素。
-
2.发明授权公开(公告)号：US07084118B2
公开(公告)日：2006-08-01
申请号：US10371778
申请日：2003-02-21
申请人： Paul Armstrong , Hal Barron , Silvano Berioli , Frederique Bigonzi , Erich Bluhmki , Richard Chin , Christopher Granger , Frans Van De Werf , Fong Wang-Clow
发明人： Paul Armstrong , Hal Barron , Silvano Berioli , Frederique Bigonzi , Erich Bluhmki , Richard Chin , Christopher Granger , Frans Van De Werf , Fong Wang-Clow
CPC分类号： A61K38/49 , G06Q99/00 , A61K2300/00
摘要： The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
摘要翻译： 本发明涉及用于治疗血栓溶解病症（例如急性心肌梗死（AMI））的改进的治疗方案。 特别地，本发明涉及治疗血栓溶解障碍，例如， AMI，与野生型人t-PA和低分子量肝素相比，具有改善的纤维蛋白特异性和延长的血浆半衰期的组织纤溶酶原激活剂（t-PA）变体的组合。
-
3.发明申请公开(公告)号：US20060205662A1
公开(公告)日：2006-09-14
申请号：US11435230
申请日：2006-05-15
申请人： Paul Armstrong , Hal Barron , Silvano Berioli , Frederique Bigonzi , Erich Bluhmki , Richard Chin , Christopher Granger , Frans De Werf , Fong Wang-Clow
发明人： Paul Armstrong , Hal Barron , Silvano Berioli , Frederique Bigonzi , Erich Bluhmki , Richard Chin , Christopher Granger , Frans De Werf , Fong Wang-Clow
IPC分类号： A61K38/18 , A61K31/727
CPC分类号： A61K38/49 , G06Q99/00 , A61K2300/00
摘要： The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
摘要翻译： 本发明涉及用于治疗血栓溶解病症（例如急性心肌梗死（AMI））的改进的治疗方案。 特别地，本发明涉及血栓溶解障碍（例如AMI）的治疗，与野生型人t-型细胞相比，组合纤溶酶原激活剂（t-PA）变体具有改善的纤维蛋白特异性和延长的血浆半衰期， PA和低分子量肝素。
-
-
搜索结果
3 条记录 (耗时 0.03 秒)
